CN109562103A - 用于治疗pik3ca相关过度生长综合征群的方法 - Google Patents

用于治疗pik3ca相关过度生长综合征群的方法 Download PDF

Info

Publication number
CN109562103A
CN109562103A CN201780011659.9A CN201780011659A CN109562103A CN 109562103 A CN109562103 A CN 109562103A CN 201780011659 A CN201780011659 A CN 201780011659A CN 109562103 A CN109562103 A CN 109562103A
Authority
CN
China
Prior art keywords
byl719
pik3ca
pros
syndrome
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780011659.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡诺德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CN202410562274.3A priority Critical patent/CN118477075A/zh
Priority to CN202410563611.0A priority patent/CN118477076A/zh
Publication of CN109562103A publication Critical patent/CN109562103A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
CN201780011659.9A 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法 Pending CN109562103A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410562274.3A CN118477075A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN202410563611.0A CN118477076A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305193.1 2016-02-19
EP16305193 2016-02-19
PCT/EP2017/053587 WO2017140828A1 (en) 2016-02-19 2017-02-17 Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410562274.3A Division CN118477075A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN202410563611.0A Division CN118477076A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Publications (1)

Publication Number Publication Date
CN109562103A true CN109562103A (zh) 2019-04-02

Family

ID=55409795

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201780011659.9A Pending CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN202410563611.0A Pending CN118477076A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN202410562274.3A Pending CN118477075A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410563611.0A Pending CN118477076A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN202410562274.3A Pending CN118477075A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Country Status (8)

Country Link
US (4) US11433059B2 (enExample)
EP (1) EP3416642A1 (enExample)
JP (3) JP7051693B2 (enExample)
KR (1) KR20180115297A (enExample)
CN (3) CN109562103A (enExample)
AU (3) AU2017219834B2 (enExample)
CA (1) CA3013845C (enExample)
WO (1) WO2017140828A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045129A1 (zh) * 2023-08-30 2025-03-06 广州嘉越医药科技有限公司 化合物用于治疗pros谱系疾病的用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296390A (en) * 2015-05-15 2022-11-01 Memorial Sloan Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
CN109562103A (zh) 2016-02-19 2019-04-02 国家医疗保健研究所 用于治疗pik3ca相关过度生长综合征群的方法
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583357A (zh) * 2006-08-29 2009-11-18 新加坡国立癌症中心 用于治疗癌症的mtor拮抗剂和血管生成抑制剂的结合物
CN105209073A (zh) * 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
IL296390A (en) * 2015-05-15 2022-11-01 Memorial Sloan Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
CN109562103A (zh) 2016-02-19 2019-04-02 国家医疗保健研究所 用于治疗pik3ca相关过度生长综合征群的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583357A (zh) * 2006-08-29 2009-11-18 新加坡国立癌症中心 用于治疗癌症的mtor拮抗剂和血管生成抑制剂的结合物
CN105209073A (zh) * 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NISHA LIMAYE, ET AL: "Somatic Activating PIK3CA Mutations Cause Venous Malformation", 《THE AMERICAN JOURNAL OF HUMAN GENETICS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045129A1 (zh) * 2023-08-30 2025-03-06 广州嘉越医药科技有限公司 化合物用于治疗pros谱系疾病的用途

Also Published As

Publication number Publication date
AU2022235569A1 (en) 2022-10-13
AU2024278598A1 (en) 2025-01-16
US20250295645A1 (en) 2025-09-25
WO2017140828A1 (en) 2017-08-24
AU2017219834A1 (en) 2018-08-23
KR20180115297A (ko) 2018-10-22
JP7051693B2 (ja) 2022-04-11
EP3416642A1 (en) 2018-12-26
CA3013845C (en) 2024-09-17
AU2022235569B2 (en) 2024-10-10
US20250339417A1 (en) 2025-11-06
CN118477076A (zh) 2024-08-13
US20200215044A1 (en) 2020-07-09
US11433059B2 (en) 2022-09-06
JP2019505549A (ja) 2019-02-28
US20220323428A1 (en) 2022-10-13
US12427141B2 (en) 2025-09-30
JP2024125429A (ja) 2024-09-18
AU2017219834B2 (en) 2022-06-30
CN118477075A (zh) 2024-08-13
CA3013845A1 (en) 2017-08-24
JP2022058800A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
AU2022235569B2 (en) BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
Lawrie et al. Paigen diet–fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1–dependent manner
Irtenkauf et al. Optimization of glioblastoma mouse orthotopic xenograft models for translational research
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
EP3294314A1 (en) Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
CN110652514A (zh) 第三代egfr抑制剂的制药用途
CN108785308B (zh) 核受体Rev-erbα的拮抗剂在制备抗腹主动脉瘤的药物中的应用
JP2024502671A (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
US20200246283A1 (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
CN103037901B (zh) 抑制cd36以控制肥胖和胰岛素敏感性
CN109806263A (zh) 一种药物组合物及其制备方法和用途
CN111447950A (zh) 活性调节剂
Wang et al. GRK2-facilitated TLR4 signaling promotes cardiac fibrosis in rheumatic mice
CN120093749A (zh) 乳腺癌的治疗
Potapenko et al. CRIZOTINIB IN TREATMENT OF ATYPICAL ALK-REARRANGED HISTIOCYTE-RICH TUMOR. CASE REPORT
CN121065177A (zh) 一种靶向ASGR1的siRNA、递送系统及其应用
CN113143922A (zh) Dhc在制备动脉粥样硬化治疗制剂中的应用
CN113244370A (zh) 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途
WO2017194031A1 (zh) 蛋白功能抑制剂dapt在制备治疗肿瘤的药物中的用途
CN105367545A (zh) 一种用于治疗唐氏综合征的化合物及其药物组合物
HK1214758A1 (en) S1p receptor modulators for treating multiple sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Paris France

Applicant after: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant after: University of Western dais, Paris

Applicant after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Address before: Paris France

Applicant before: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant before: University of Paris

Applicant before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20221222

Address after: Paris France

Applicant after: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant after: University of Paris

Applicant after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Address before: Paris France

Applicant before: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant before: UNIVERSITE PARIS DESCARTES

Applicant before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20190402

RJ01 Rejection of invention patent application after publication